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Hepassocin as a treatment
for fulminant hepatic failure:
will it translate from rats
to human?
Vincenza Calvaruso
Acute liver failure (ALF) is defined as the
abrupt loss of hepatic cellular function in
a patient without pre-existing liver dis-
ease, with the subsequent development of
coagulopathy, jaundice and encephalop-
athy. It remains one of the most chal-
lenging medical emergencies, due to the
multiorgan nature of the disease, the rapid
evolution of the clinical condition and
the need for multidisciplinary supportive
interventions in order to assess the
necessity for liver transplantation (LT)
correctly.1
Despite different causes of ALF, the
mode of cell death typically follows one of
two patterns: necrosis or apoptosis; apo-
ptosis is manifest by nuclear and cyto-
plasmic shrinkage without disturbance of
cell membrane integrity or liberation of
intracellular content. Consequently, second-
ary inflammation is not a feature. Necrosis
involves depletion of ATP with resultant
cell swelling and lysis, leading to release of
cellular content and secondary inflamma-
tion. However, there is increasing evidence
that they are alternative outcomes of the
same initiating factors and signalling path-
ways, a process known as necroapoptosis.2
The main mechanism of liver cell death in
ALF is the activation of cell membrane
receptors. The cytokine, tumour necrosis
factor a (TNFa), and the Fas ligandmediate
hepatocellular death through interaction
with structurally related cell membrane
receptors. In addition to TNFa, other
proinflammatory and anti-inflammatory
cytokines may have a role in the patho-
genesis of acute liver injury of various
aetiologies, both experimentally and clini-
cally. Although all the factors responsible
for regeneration in the setting of such
severe liver cell loss remain incompletely
understood, it has been shown that in-
creased circulating levels of TNFa and
other cytokines such as interleukin-6 (IL-6)
are key initiators of liver regeneration.
Other mechanisms involved in regenera-
tion are the elevation of plasma levels of
stimulatory hepatocyte growth factor
(HGF) and inhibitory transforming growth
factor b (TGFb), presumably due to release
from damaged extracellular matrix.
Furthermore, increased activity of the fibri-
nolytic system, responsible for activation of
bothHGFandTGFb, is also evident.3Onthe
basis of these findings, therapeutic options
to bridge patients to recovery or LTcan be
investigated and, in terms of potential
clinical applications, functional studies
using animalmodels are absolutely crucial,
albeit not always translatable to the human
setting.
In this issue of Gut, Li et al (see page
817) demonstrate in a rat model of
fulminant hepatic failure (FHF) that
administration of recombinant human
hepassocin (HPS) after D-galactose and
carbon tetrachloide (CCl4) treatment
protected against the liver injury, reduced
apoptosis and enhanced proliferation.4
HPS, also named hepatocyte-derived
fibrinogen-related protein-1 (HFREP-1),
belongs to a fibrinogen family and has
been found to be present in plasma and to
associate non-covalently with the fibrin
matrix of a plasma clot.5
HPS was first isolated in a rat model
using differential cDNA expression clon-
ing of a cDNA6; the authors have found
that mRNA expression of this factor is
upregulated in the rat liver after partial
hepatectomy, suggesting its potential role
as a potent mitogenic growth factor in the
process of liver regeneration.6
Moreover, the same group cloned the
humancounterpart of ratHPS todetermine
if HPS is also implicated in liver regenera-
tion in humans, and they concluded that
during liver regeneration the expression of
HPS mRNAwas strongly upregulated.7
After the confirmation that recombi-
nant human HPS is a specific mitogenic
factor on human hepatocytes in vitro,
Li et al4 assessed the effect of human HPS
on growth of hepatocytes in vivo. The
administration of HPS to rats with partial
hepatectomy (PHx) or liver injury induced
by D-galactose and CCl4 indicated that
recombinant human HPS exerted an im-
portant role in promoting cell proliferation
in hepatocytes in vivo. It significantly
inhibited the development of FHF in both
models by preventing the high mortality
rate and improving liver histology in the
HPS treatment group that showed signif-
icantly less hepatic necrosis.
The authors also investigated the role of
HPS on apoptotic mechanisms and the
results revealed that HPS is able to inhibit
the upregulation of proapoptotic factors
(Bax, cleaved caspase 9) induced by toxin,
while increasing the expression level of
antiapoptotic factors (Bcl-2, Bcl-xL). Fur-
thermore, lack of expression of HPS by
RNA interference resulted in hepatocyte
growth inhibition, suggesting that human
HPS may be one of the endogenous phys-
iological regulators of hepatocyte prolifer-
ation. This focuses on the potential role of
HPS in the management of patients with
acute hepatitis with ALF.
In this setting, the assessment of HPS
expression might correlate with the prog-
nosis and the likelihood of recovery or
continuing hepatic failure, and conse-
quently the rate of survival or LT. HPS
expression could be different according to
the aetiology of liver damage and/or other
patient demographic and clinical features.
Genetic mutations of the HPS gene may
be discovered and could be causal in rela-
tion to the absence of protection against
liver injury and to impaired liver regener-
ation. This can be useful in the setting
of drug-induced liver injury, mostly in
patients who would need long-term
treatment with potentially hepatotoxic
drugs.
Moreover, the therapeutic role of HPS
should be investigated. Li et al4 focused
on the protective role of HPS that results
in a reduction of liver necrosis, lower levels
of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST), and
decreased lethality. There could be several
clinical applications of this finding and
although ALF is likely to be the setting
for this growth factor, HPS expression
assessment and/or HPS administration
may extend, in the future, to the treat-
ment of exacerbations of chronic liver
diseases. This is supported by the inter-
esting finding that human HPS did not
promote DNA synthesis in established cell
lines such as HepG2 (human hepatocarci-
noma) or HeLa, PC12 and NIH/3T3 cells
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(non-liver derived cells). It is assumed that
HPS only acts on normal hepatocytes,
possibly because its receptor is only
present in normal hepatocytes.4 7
Furthermore, in line with these results,
HFREP-1 has been found to be specifically
expressed in normal human liver tissue,
but reduced or undetectable in most
hepatocellular carcinoma (HCC) specimens
at both the RNA and protein level, sug-
gesting that it might possess growth sup-
pression activity in this context.8 How
can we interpret these findings? Can we
suppose that tissue and/or serum HPS
expression may be significantly different
in patients with chronic liver disease
according to their rate of development of
HCC? Should we promote further inves-
tigation on the potential growth suppres-
sion activity of HPS on HCC to evaluate its
potential role in HCC systemic treatment?
We should not forget that this study,
like all studies performed on animal
models, suffers from the limitations
related to the transferability of the results
to the human setting. In fact, no direct
data have shown the upregulation of HPS
in humans.
Moreover, the disadvantage of surgical
models such as the hepatectomised animal
is that these models lack the milieu of
inflammatory mediators produced by
damaged and/or necrotic hepatic cells. This
limits the pathophysiological study of
certain systemic features of ALF. Another
limitation of the therapeutic applications
of HPS could be the potential procoagulant
effects that need to be investigated accu-
rately in order to evaluate the risk of
thrombotic events.
What is truly exciting about this study
is the strong correlation between HPS
expression and improvement of hepatic
regenerative activity and the reduction of
hepatocyte apoptosis in toxin-induced liver
disease.
Future research on the assessment and
the administration of HPS will lead to a
new therapeutic strategy for the manage-
ment and treatment of liver disease.
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Role of microRNA in IBS with
increased gut permeability
Marı́a Vicario, Cristina Martı́nez, Javier Santos
Paradoxically, irritable bowel syndrome
(IBS), a leading reason for medical
consultation, is presently lacking sensitive
and specific biological markers, and hence
its diagnosis still relies on clinical
symptom-based criteria. Luckily, and in
close liaison with the progressive advent
of innovative and ultrasensitive technolo-
gies and their rapid incorporation into
research protocols, our mechanistic
understanding of the origin of IBS may be
undergoing a giant leap forward. One such
remarkable advance could be the identifi-
cation of a pathophysiological substrate
common to the intestine of some patients
with IBSdthat is, a combined process of
low-grade mucosal inflammation and
immune activation, and disruption of the
epithelial barrier.1e4 Physical and func-
tional disintegrity of the intestinal barrier,
reflected by distorted expression patterns
of key selective transporters and structural
proteins, and enhanced permeability, also
characterises a number of inflammatory
conditions including coeliac disease,
inflammatory bowel disease, food allergy
or type 1 diabetes, suggesting a role in
disease pathogenesis.5 As for IBS, this may
also be clinically relevant because the
grade of barrier dysfunction has been
related to the onset and severity of
abdominal pain and visceral hypersensi-
tivity.6 Interestingly, the above observa-
tions, although not unique to patients
with diarrhoea-predominant IBS (d-IBS),
tend to predominate in this IBS subtype.
MicroRNAs (miRNAs) are 18e25
nucleotide long RNAs serving as master
endogenous fine-tuners of gene expression
commonly operating via partial binding
complementarity to target mRNAs.
Indeed, the stability and functional
expression of at least 30% of all protein-
coding human genes are governed by
miRNAs, acting primarily but not exclu-
sively at the post-transcriptional level.7 In
humans, the low grade repression induced
by miRNAs, rarely exceeding twofold,8
mainly affects protein translation and
infrequently causes degradation or cleavage
of the cognate mRNA. In mammals,
miRNAs comprise 2e3% of genes, found
spread throughout the genome, with the
exception of the Y chromosome, with
w700 different sequences so far identified
in humans (miRBase 14.0). While current
computational estimations predict dozens
to thousands of targets for each single
miRNA, their dominant pattern of expres-
sion is tissue or cell type specific.9
Only a small fraction of miRNAs have
been functionally characterised in detail.
However, as witnessed by growing and
compelling documentation, these mole-
cules harbour a vast competence to impact
on every cellular process, from survival
and renewal to apoptosis, and, by
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Autònoma de Barcelona, Barcelona, Spain
Correspondence to Dr Javier Santos, Department of
Gastroenterology, Digestive Diseases Research Unit,
Institut de Recerca Vall d’Hebron, CIBERehd, Hospital
Universitari Vall d’Hebron, Universitat Autònoma de
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